RBC Raises Neurocrine Biosciences Price Target to $190 From $187
RBC maintained its Outperform rating on Neurocrine Biosciences.
Related stories
Upwork raises annual adjusted profit forecast; shares rise 2.7%
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Proto Labs Raises Multi Jet Fusion 3D Printing Capacity by 50%
Proto Labs said it raised its HP Multi Jet Fusion 3D-printing capacity by 50%.
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Volaris shares surge 10% after opening
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
SBI shares fall 1.70% despite stronger Q2 performance
State Bank of India shares closed at Rs.970 after erasing intraday gains, despite September-quarter results coming in ahead of Street estimates.
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC
Knife River Reports Q3 EPS of $2.43, Trims 2026 Revenue Guidance
Third-quarter revenue was $1.28 billion. EPS and revenue were below FactSet estimates of $2.60 and $1.30 billion, respectively; 2026 revenue guidance is $3.38 billion to $3.43 bill
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC
Utkarsh Small Finance Bank Reports Q2 Net Loss of 698.5 Million Rupees
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC